1800 202 8726
Do You Really Need a Biopsy?

Is a Biopsy Needed If — the Cancer Is Already Obvious?

A scan can show that a mass is there. It cannot say what type of cancer it is, what is driving its growth, or which treatment to use. The biopsy answers a different set of questions — and those answers are what make a treatment plan possible.

Medically reviewed by Dr. Mohammed Imaduddin, Surgical Oncologist, MBBS · MS (General Surgery) · M.Ch (Surgical Oncology) · Last reviewed September 2026

  • The scan confirms presence — It does not identify the cancer type, subtype, or the markers that guide treatment decisions.
  • Two identical masses can need opposite treatments — Molecular differences in the tumour tissue, invisible on imaging, determine which regimen applies to each.
  • Markers live in the tissue, not the image — PD-L1, HER2, EGFR, MSI — these guide targeted therapy and immunotherapy choices and are found only by testing the sample.
  • Skipping the biopsy removes options — A treatment started without biomarker results may miss a targeted drug that would have worked better.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Talk to a medical oncologist

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

A scan can show that a mass is there — it cannot tell your team what type of cancer it is, what is driving its growth, or which treatment to use. NCCN and ESMO guidance treats tissue sampling as essential before starting treatment in almost all solid tumours, because the molecular profile determines the regimen.

Why does the team need a sample when the scan already shows a mass?

A scan tells your oncologist that something is there and roughly where it is. It does not tell them what kind of cancer it is, which subtype, or what is driving its growth.

Two masses that look identical on a scan can behave completely differently and need completely different treatments. The difference is in the tissue, not the image.

Your team is not doing the biopsy to confirm the mass is there. They are doing it to answer a different set of questions — and those answers are what make a treatment plan possible.

What does the sample tell your team that the scan cannot?

Tissue analysis confirms the exact cancer type and subtype. For lung cancer, whether it is adenocarcinoma or squamous cell changes both the staging workup and the drugs used.

The sample is also tested for biomarkers — such as PD-L1, HER2, EGFR, KRAS, and microsatellite instability — that determine whether targeted therapy or immunotherapy is likely to work for your specific tumour.

When cancer has spread and the primary site is not clear, pathology on the biopsy sample can often identify where it originally started. Treatment is guided by the origin, not only the site where the mass was found.

What can a biopsy tell your doctor that a scan cannot?

  • Cancer type and subtype — confirmed by a pathologist, not inferred from the image
  • Tumour grade — how fast the cells are dividing
  • PD-L1 expression — determines eligibility for immunotherapy
  • Driver mutations — EGFR, ALK, KRAS, BRAF and others that targeted drugs are designed to act on
  • HER2, ER and PR receptor status — critical for breast and some other cancers
  • Microsatellite instability and tumour mutational burden — relevant to immunotherapy across cancer types
  • Primary site of origin — when the mass found is a metastasis and the starting point is unclear

Not sure what this means for you?

Share your reports and a senior oncologist will explain your options in plain language — no obligation to start treatment.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

You do not have to work this out alone

A 45-minute consultation with a specialist who treats this every week.

Book Free Consultation Call 1800 202 8726

What can a scan show, and what does the tissue sample add?

InformationCT / PET-CT scanBiopsy and tissue analysis
Mass is presentShows clearlyNot the purpose of this test
Location and sizeShows wellNot the purpose of this test
Cancer typeCannot determineConfirmed by a pathologist
SubtypeCannot determineYes — determines treatment choice
Biomarkers for targeted therapy or immunotherapyCannot determineYes — tested from the sample
Driver mutationsCannot determineYes — molecular profiling of the sample
Tumour gradeCannot determineYes — assessed from the cells

Did you know?

Two patients with lung cancer that looks identical on a scan can receive completely different regimens — one standard chemotherapy, one a daily oral targeted tablet — because their tumours carry different molecular profiles.

The biopsy is what reveals which profile is present. Without that information, there is no evidence-based basis for choosing between them.

Source: NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer

What if you want to start treatment before the biopsy results are back?

Can treatment start before the full biopsy results are back?

In most cases, starting treatment before tissue analysis is complete means starting without the information that determines which treatment is appropriate. For solid tumours, NCCN and ESMO guidance is that pathological confirmation should come before systemic treatment begins. There are rare situations — a rapidly growing tumour where delay poses its own risk — where your oncologist may weigh the timing differently, but that is a clinical judgement for your team, not a general rule. If you are concerned about the wait, ask your oncologist for the expected timeline and why it matters to have the results first.

Are there cancers where a biopsy is genuinely not possible?

Yes, in a small number of cases the location of the tumour makes tissue sampling too risky — for example, close to a major blood vessel, or in a part of the brain where the procedure could cause harm that outweighs the benefit. In those situations your oncologist will explain why and what the alternative is: sometimes imaging characteristics alone meet diagnostic criteria, sometimes a different sampling site is used, and sometimes a liquid biopsy provides partial molecular information. This is an uncommon situation and your team will tell you if it applies to your case.

What if the biopsy procedure feels risky or painful?

The concern is understandable, and it is worth raising directly with your oncologist before making a decision. Many biopsies are done under local anaesthetic as a day procedure, and the level of discomfort varies considerably by location. Your team can explain what the specific procedure involves, what pain management is used, and what the complication rate is for your case. Asking for that information before you consent is a reasonable request. The risk of the procedure is usually far smaller than the risk of choosing the wrong treatment.

Is a liquid biopsy the same as a tissue biopsy?

No, and they are not interchangeable for the initial diagnosis in most cases. A liquid biopsy analyses fragments of tumour DNA circulating in a blood sample. It can be useful for monitoring treatment response or detecting resistance mutations when a treatment stops working, and it avoids a surgical procedure. However, for the initial diagnosis and biomarker profiling that guides the first treatment decision, tissue sampling remains the standard that NCCN, ESMO and ICMR guidance recommends. Whether a liquid biopsy has a role in your situation is a question to raise with your oncologist.

Can we get a second opinion on the biopsy report?

Yes, and for rare tumours or borderline results, a second pathology opinion is specifically recommended in ESMO and NCCN guidance. If the diagnosis is an uncommon cancer type, or if there is any uncertainty about the subtype or a biomarker result, asking for the slides to be reviewed by a specialist pathologist at another centre is a reasonable and common request. The tissue sample and the report belong to you. Ask your treating team how to arrange an external review if you want one.

How long does it take to get the full results, including marker tests?

The timeline varies by the tests required. Basic pathology — confirming the cancer type — typically takes a few days to a week once the sample reaches the laboratory. Biomarker testing, including PD-L1 expression, microsatellite instability, and molecular profiling for driver mutations, can take longer depending on which markers are being tested and whether the sample needs to go to a specialist laboratory. Ask your team to give you an expected date for each result so you are not waiting without a timeline to plan around.

Explore 71 more Understanding Your Biopsy and Whether You Need One topics

HUB — Does a Biopsy Spread Cancer? Myths and Evidence

HUB — What Is a Biopsy? Everything You Need to Know

All Understanding Your Biopsy and Whether You Need One →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

Can a doctor tell from the scan what type of cancer it is?

Not reliably. Imaging can suggest possibilities — a mass in the lung of a smoker raises one set of concerns, a liver lesion another — but the scan does not confirm the cancer type and cannot distinguish subtypes. Two tumours that look almost identical on imaging can be biologically very different and need completely different treatments. Pathological confirmation from tissue is the standard that NCCN, ESMO and ICMR guidance requires before treatment decisions are made.

What if the biopsy result is different from what the scan suggested?

This happens, and when it does, the pathology result takes precedence. Imaging is a useful guide to where to look and whether something has changed in size, but it does not determine the tumour type. When a biopsy comes back as something other than expected — a different cancer type, a different subtype, or even a benign process — the treatment plan changes accordingly. This is one of the reasons the biopsy is not a formality: it sometimes changes the diagnosis entirely.

Is there any situation where treatment starts without a biopsy?

In a small number of cases — a tumour location that makes biopsy too risky, or a clinical picture clear enough that imaging combined with clinical findings meets diagnostic criteria — your oncologist may proceed without tissue sampling. This is unusual and your team will explain their reasoning. The important point is that the decision belongs to your treating doctor based on your specific case. If you have not been told why a biopsy is or is not planned, ask.

What is a liquid biopsy and can it replace a tissue biopsy?

A liquid biopsy is a blood test that detects fragments of tumour DNA circulating in the bloodstream. It can identify certain mutations without a surgical procedure and is increasingly used to monitor treatment response or detect resistance mutations when a treatment stops working. For the initial diagnosis and biomarker profiling that guides the first treatment decision, tissue sampling remains the standard in most cases. Whether a liquid biopsy has a role in your situation is a question your oncologist can answer with reference to your specific cancer type.

How long does it take to get biopsy results including the marker tests?

Basic pathology — confirming the cancer type — typically takes a few days to a week once the sample reaches the laboratory. Biomarker testing, including PD-L1, microsatellite instability, and molecular profiling for driver mutations, can take longer depending on which markers apply to your cancer type. Ask your team to give you an expected date for each result. It is reasonable to have a specific date to plan around rather than an open-ended wait.

Is immunotherapy available at CION if the biopsy shows I may be eligible?

Yes. If your biopsy results show markers that indicate immunotherapy may be appropriate — such as PD-L1 expression, high microsatellite instability, or high tumour mutational burden — your oncologist will discuss whether it is indicated for your cancer type and stage. Immunotherapy is administered as day care at CION centres. Response-assessment imaging such as PET-CT is coordinated with partner imaging centres. CION does not provide CAR-T or cell therapy; if that becomes relevant to your case, you would be referred to a centre that offers it.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation